BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treatment Reviews 2019;73:20-30. [DOI: 10.1016/j.ctrv.2018.12.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
Number Citing Articles
1 Scholl C, Fröhling S. Exploiting rare driver mutations for precision cancer medicine. Curr Opin Genet Dev 2019;54:1-6. [PMID: 30844512 DOI: 10.1016/j.gde.2019.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
2 Wallerstedt SM, Nilsson Ek A, Olofsson Bagge R, Kovács A, Strandell A, Linderholm B. Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:1199-211. [PMID: 32504183 DOI: 10.1007/s00228-020-02914-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Snowdon C, Kernaghan S, Moretti L, Turner NC, Ring A, Wilkinson K, Martin S, Foster S, Kilburn LS, Bliss JM. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Trials 2022;23:372. [PMID: 35526005 DOI: 10.1186/s13063-022-06312-x] [Reference Citation Analysis]
4 Chu KJ, Ma YS, Jiang XH, Wu TM, Wu ZJ, Li ZZ, Wang JH, Gao QX, Yi B, Shi Y, Wang HM, Gu LP, Zhang SQ, Wang GR, Liu JB, Fu D, Jiang XQ. Whole-Transcriptome Sequencing Identifies Key Differentially Expressed mRNAs, miRNAs, lncRNAs, and circRNAs Associated with CHOL. Mol Ther Nucleic Acids 2020;21:592-603. [PMID: 32721879 DOI: 10.1016/j.omtn.2020.06.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
5 Lévy V. Of some innovations in clinical trial design in hematology and oncology. Therapie 2021:S0040-5957(21)00245-6. [PMID: 34922739 DOI: 10.1016/j.therap.2021.10.011] [Reference Citation Analysis]
6 Nosrati M, Nikfar S. Conducting economic evaluation based on basket clinical trial in the area of precision medicine. Expert Rev Pharmacoecon Outcomes Res 2021;21:169-71. [PMID: 33356657 DOI: 10.1080/14737167.2021.1865158] [Reference Citation Analysis]
7 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tidwell RSS, Peng SA, Chen M, Liu DD, Yuan Y, Lee JJ. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clin Trials 2019;16:645-56. [PMID: 31450957 DOI: 10.1177/1740774519871471] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
9 Jones HM Markham-Jones, Curtis F, Law G, Bridle C, Boyle D, Ahmed T. Evaluating follow-up and complexity in cancer clinical trials (EFACCT): an eDelphi study of research professionals' perspectives. BMJ Open 2020;10:e034269. [PMID: 32075839 DOI: 10.1136/bmjopen-2019-034269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Doroshow DB, Doroshow JH. From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. Cancer J 2019;25:245-53. [PMID: 31335388 DOI: 10.1097/PPO.0000000000000386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lengliné E, Peron J, Vanier A, Gueyffier F, Kouzan S, Dufour P, Guillot B, Blondon H, Clanet M, Cochat P, Degos F, Chevret S, Grande M, Putzolu J; Transparency Committee of the French National Authority for Health. Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment. Lancet Oncol 2021;22:e430-4. [PMID: 34592192 DOI: 10.1016/S1470-2045(21)00337-5] [Reference Citation Analysis]
12 Rios JD, Velummailum R, Bennett J, Nobre L, Tsang DS, Bouffet E, Hawkins C, Tabori U, Denburg A, Pechlivanoglou P. Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma. BMC Pediatr 2022;22:13. [PMID: 34980048 DOI: 10.1186/s12887-021-03069-1] [Reference Citation Analysis]
13 Pierobon M, Robert NJ, Northfelt DW, Jahanzeb M, Wong S, Hodge KA, Baldelli E, Aldrich J, Craig DW, Liotta LA, Avramovic S, Wojtusiak J, Alemi F, Wulfkuhle JD, Bellos A, Gallagher RI, Arguello D, Conrad A, Kemkes A, Loesch DM, Vocila L, Dunetz B, Carpten JD, Petricoin EF, Anthony SP. Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial. Mol Oncol 2021. [PMID: 34437759 DOI: 10.1002/1878-0261.13091] [Reference Citation Analysis]
14 Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, Geissler J, Husereau D, Martinez-Lopez I, Normanno N, Reis-Filho JS, Stefani S, Thomas DM, Westphalen CB, Voest E. Delivering precision oncology to patients with cancer. Nat Med 2022;28:658-65. [PMID: 35440717 DOI: 10.1038/s41591-022-01717-2] [Reference Citation Analysis]
15 Liu JB, Chu KJ, Ling CC, Wu TM, Wang HM, Shi Y, Li ZZ, Wang JH, Wu ZJ, Jiang XQ, Wang GR, Ma YS, Fu D. Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization. Curr Probl Cancer 2020;44:100612. [PMID: 32517878 DOI: 10.1016/j.currproblcancer.2020.100612] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Faulkner E, Spinner DS, Ringo M, Carroll M. Are Global Health Systems Ready for Transformative Therapies? Value in Health 2019;22:627-41. [DOI: 10.1016/j.jval.2019.04.1911] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
17 Adamaki M, Zoumpourlis V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther 2021;228:107932. [PMID: 34174272 DOI: 10.1016/j.pharmthera.2021.107932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Speers MA. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program. Pharm Med 2019;33:89-98. [DOI: 10.1007/s40290-019-00274-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Khan SS, Chen AP, Takebe N. Impact of NCI-MATCH: a Nationwide Oncology Precision Medicine Trial. Expert Review of Precision Medicine and Drug Development 2019;4:251-8. [DOI: 10.1080/23808993.2019.1623023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Cipriani A, Ioannidis JPA, Rothwell PM, Glasziou P, Li T, Hernandez AF, Tomlinson A, Simes J, Naci H. Generating comparative evidence on new drugs and devices after approval. Lancet 2020;395:998-1010. [PMID: 32199487 DOI: 10.1016/S0140-6736(19)33177-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
21 Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt HHHW. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci 2021:S0165-6147(21)00221-2. [PMID: 34895945 DOI: 10.1016/j.tips.2021.11.004] [Reference Citation Analysis]
22 Siden EG, Park JJ, Zoratti MJ, Dron L, Harari O, Thorlund K, Mills EJ. Reporting of master protocols towards a standardized approach: A systematic review. Contemp Clin Trials Commun 2019;15:100406. [PMID: 31334382 DOI: 10.1016/j.conctc.2019.100406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
23 Gaultney JG, Bouvy JC, Chapman RH, Upton AJ, Kowal S, Bokemeyer C, Solà-Morales O, Wolf J, Briggs AH. Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies. Appl Health Econ Health Policy 2021;19:625-34. [PMID: 34028672 DOI: 10.1007/s40258-021-00654-4] [Reference Citation Analysis]
24 Fiste O, Liontos M, Koutsoukos K, Terpos E, Dimopoulos MA, Zagouri F. Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. Ann Transl Med 2020;8:1603. [PMID: 33437802 DOI: 10.21037/atm-20-1175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Exley AR, Rantell K, McBlane J. Clinical development of cell therapies for cancer: The regulators' perspective. Eur J Cancer 2020;138:41-53. [PMID: 32836173 DOI: 10.1016/j.ejca.2020.07.006] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Pappas DA, Brittle C, Mossell JE 3rd, Withers JB, Lim-Harashima J, Kremer JM. Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study. Rheumatol Int 2021;41:585-93. [PMID: 33258003 DOI: 10.1007/s00296-020-04746-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Haslam A, Kim MS, Prasad V. Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. Ann Oncol 2021;32:926-32. [PMID: 33862157 DOI: 10.1016/j.annonc.2021.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
28 Di Paolo A, Arrigoni E, Luci G, Cucchiara F, Danesi R, Galimberti S. Precision Medicine in Lymphoma by Innovative Instrumental Platforms. Front Oncol 2019;9:1417. [PMID: 31921674 DOI: 10.3389/fonc.2019.01417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
29 O'Leary TJ. Rigor, Reproducibility, and the P Value. Am J Pathol 2021;191:805-8. [PMID: 33689793 DOI: 10.1016/j.ajpath.2021.03.001] [Reference Citation Analysis]
30 Wang JY, Sarin KY. Dermatology Advances Into an Era of Precision Medicine. JAMA Dermatol 2021;157:770-2. [PMID: 34076667 DOI: 10.1001/jamadermatol.2021.0024] [Reference Citation Analysis]
31 Tully B, Balleine RL, Hains PG, Zhong Q, Reddel RR, Robinson PJ. Addressing the Challenges of High-Throughput Cancer Tissue Proteomics for Clinical Application: ProCan. Proteomics 2019;19:e1900109. [PMID: 31321850 DOI: 10.1002/pmic.201900109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
32 Imaoka H, Sasaki M, Hashimoto Y, Watanabe K, Ikeda M. New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. J Clin Med 2019;8:E1173. [PMID: 31387310 DOI: 10.3390/jcm8081173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
33 Szeto C, Kurzrock R, Kato S, Goloubev A, Veerapaneni S, Preble A, Reddy S, Adashek J. Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials. ESMO Open 2022;7:100396. [DOI: 10.1016/j.esmoop.2022.100396] [Reference Citation Analysis]
34 Baumgart SJ, Nevedomskaya E, Haendler B. Dysregulated Transcriptional Control in Prostate Cancer. Int J Mol Sci 2019;20:E2883. [PMID: 31200487 DOI: 10.3390/ijms20122883] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
35 Doroshow DB, Doroshow JH. Genomics and the History of Precision Oncology. Surg Oncol Clin N Am 2020;29:35-49. [PMID: 31757312 DOI: 10.1016/j.soc.2019.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
36 Meyer EL, Mesenbrink P, Dunger-baldauf C, Fülle H, Glimm E, Li Y, Posch M, König F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics 2020;42:1330-60. [DOI: 10.1016/j.clinthera.2020.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
37 Chiarini F, Evangelisti C, Lattanzi G, McCubrey JA, Martelli AM. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. Biochim Biophys Acta Mol Cell Res 2019;1866:1322-37. [PMID: 30928610 DOI: 10.1016/j.bbamcr.2019.03.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
38 Kreutzer FP, Meinecke A, Schmidt K, Fiedler J, Thum T. Alternative strategies in cardiac preclinical research and new clinical trial formats. Cardiovasc Res 2021:cvab075. [PMID: 33693475 DOI: 10.1093/cvr/cvab075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Ajmera Y, Singhal S, Dwivedi SN, Dey AB. The changing perspective of clinical trial designs. Perspect Clin Res 2021;12:66-71. [PMID: 34012901 DOI: 10.4103/picr.PICR_138_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Puente J, Gascon F, Ponte B, de la Fuente D. On strategic choices faced by large pharmaceutical laboratories and their effect on innovation risk under fuzzy conditions. Artif Intell Med 2019;100:101703. [PMID: 31607342 DOI: 10.1016/j.artmed.2019.101703] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Vanderbeek AM, Bliss JM, Yin Z, Yap C. Implementation of platform trials in the COVID-19 pandemic: A rapid review. Contemp Clin Trials 2021;112:106625. [PMID: 34793985 DOI: 10.1016/j.cct.2021.106625] [Reference Citation Analysis]
42 Roby-Brami A, Jarrassé N, Parry R. Impairment and Compensation in Dexterous Upper-Limb Function After Stroke. From the Direct Consequences of Pyramidal Tract Lesions to Behavioral Involvement of Both Upper-Limbs in Daily Activities. Front Hum Neurosci 2021;15:662006. [PMID: 34234659 DOI: 10.3389/fnhum.2021.662006] [Reference Citation Analysis]
43 Lin B, Wang Y, Zhao K, Lü WD, Hui X, Ma Y, Lv R. Exosome-based rare earth nanoparticles for targeted in situ and metastatic tumor imaging with chemo-assisted immunotherapy. Biomater Sci 2021. [PMID: 34940770 DOI: 10.1039/d1bm01809d] [Reference Citation Analysis]
44 Li X, Sigworth EA, Wu AH, Behrens J, Etemad SA, Nagpal S, Go RS, Wuichet K, Chen EJ, Rubinstein SM, Venepalli NK, Tillman BF, Cowan AJ, Schoen MW, Malty A, Greer JP, Fernandes HD, Seifter A, Chen Q, Chowdhery RA, Mohan SR, Dewdney SB, Osterman T, Ambinder EP, Buchbinder EI, Schwartz C, Abraham I, Rioth MJ, Singh N, Sharma S, Gibson MK, Yang PC, Warner JL. Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis. Sci Rep 2020;10:17536. [PMID: 33067482 DOI: 10.1038/s41598-020-73466-6] [Reference Citation Analysis]
45 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Litman T. Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases. APMIS 2019;127:386-424. [PMID: 31124204 DOI: 10.1111/apm.12934] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
47 Di Liello R, Piccirillo MC, Arenare L, Gargiulo P, Schettino C, Gravina A, Perrone F. Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials. Life (Basel) 2021;11:1253. [PMID: 34833129 DOI: 10.3390/life11111253] [Reference Citation Analysis]
48 Lara Gongora AB, Carvalho Oliveira LJ, Jardim DL. Impact of the biomarker enrichment strategy in drug development. Expert Review of Molecular Diagnostics 2020;20:611-8. [DOI: 10.1080/14737159.2020.1711734] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Imaoka H, Sasaki M, Hashimoto Y, Watanabe K, Miyazawa S, Shibuki T, Mitsunaga S, Ikeda M. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics (Basel) 2021;11:1195. [PMID: 34209310 DOI: 10.3390/diagnostics11071195] [Reference Citation Analysis]
50 Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, Booth CM. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncol 2021;7:728-34. [PMID: 33764385 DOI: 10.1001/jamaoncol.2021.0379] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
51 Soldatos TG, Kaduthanam S, Jackson DB. Precision Oncology-The Quest for Evidence. J Pers Med 2019;9:E43. [PMID: 31492009 DOI: 10.3390/jpm9030043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
52 Simons M, Van De Ven M, Coupé V, Joore M, IJzerman M, Koffijberg E, Frederix G, Uyl-De Groot C, Cuppen E, Van Harten W, Retèl V. Early technology assessment of using whole genome sequencing in personalized oncology. Expert Rev Pharmacoecon Outcomes Res 2021;21:343-51. [PMID: 33910430 DOI: 10.1080/14737167.2021.1917386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Mezghiche I, Yahia-Cherbal H, Rogge L, Bianchi E. Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers. Expert Rev Clin Immunol 2021;17:331-54. [PMID: 33622154 DOI: 10.1080/1744666X.2021.1894926] [Reference Citation Analysis]
54 Harvey MJ, Cunningham R, Sawchyn B, Montesion M, Reddy P, McBride A, Chawla AJ. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol 2021;5:1611-24. [PMID: 34994647 DOI: 10.1200/PO.20.00540] [Reference Citation Analysis]
55 Turner JH. Real-World Evidence of Clinical Outcomes in Precision Radionuclide Oncology: The NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer. Curr Pharm Des 2020;26:3799-803. [PMID: 32164507 DOI: 10.2174/1381612826666200312141347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
56 Ouellette SB. Landscape of granted US patents in personalized diagnostics for oncology from 2014 to 2018. Expert Opin Ther Pat 2019;29:191-8. [PMID: 30712415 DOI: 10.1080/13543776.2019.1575809] [Reference Citation Analysis]
57 Bell RJ. Don’t skip the methods section! Randomized controlled trials are not all the same. Climacteric 2020;23:224-5. [DOI: 10.1080/13697137.2020.1732916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Superchi C, Brion Bouvier F, Gerardi C, Carmona M, San Miguel L, Sánchez-Gómez LM, Imaz-Iglesia I, Garcia P, Demotes J, Banzi R, Porcher R; PERMIT Group. Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ Open 2022;12:e052926. [PMID: 35523482 DOI: 10.1136/bmjopen-2021-052926] [Reference Citation Analysis]
59 Sezen D, Verma V, He K, Abana CO, Barsoumian H, Ning MS, Tang C, Hurmuz P, Puebla-Osorio N, Chen D, Tendler I, Comeaux N, Nguyen QN, Chang JY, Welsh JW. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol 2021;31:217-26. [PMID: 34090648 DOI: 10.1016/j.semradonc.2021.02.005] [Reference Citation Analysis]
60 Kwon EJ, Ha M, Jang JY, Kim YH. Identification and Complete Validation of Prognostic Gene Signatures for Human Papillomavirus-Associated Cancers: Integrated Approach Covering Different Anatomical Locations. J Virol 2021;95:e02354-20. [PMID: 33361419 DOI: 10.1128/JVI.02354-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Kesselmeier M, Benda N, Scherag A. Effect size estimates from umbrella designs: Handling patients with a positive test result for multiple biomarkers using random or pragmatic subtrial allocation. PLoS One 2020;15:e0237441. [PMID: 32797088 DOI: 10.1371/journal.pone.0237441] [Reference Citation Analysis]